Zietek, T., Rath, E., Haller, D., Daniel, H., & Mssig, K
Based on the reluctance of major Part D plan sponsors to participate in the BALANCE Model in 2027 under the original specifications, it appears that sponsors had insufficient data to estimate their added costs associated with covering GLP-1s for obesity
Because they have personally experienced a reduced desire for food, they are more likely to anticipate a decline in overall demand, translating into lower revenues and profitability expectations for restaurants, grocery stores, and food manufacturers
In South Africa, it is a Schedule 4 medicine authorised for type 2 diabetes in adults
A GLP-1 pill wouldnt need sophisticated cold-chain distribution and storage, meaning it could be sold in countries that dont have that infrastructure